TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:24
Ambrx Biopharma Inc. ( AMAM ) https://ambrx.com
13.99USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
AMAM
763.58%
SPY
30.72%
AMAM
0.00%
SPY
112.82%
AMAM
0.00%
SPY
201.04%
AMAM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
931.27
935.95
0.64
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-13.42
270.32
3.84
-6.98
0.00
-13.60
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-48350.94
100.00
-1997.27
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-56.00
-51.65
0.00
Other Earnings and Cash Flow Stats:
Ambrx Biopharma Inc. ( AMAM ) Net Income TTM ($MM) is -64.80
Ambrx Biopharma Inc. ( AMAM ) Operating Income TTM ($MM) is -59.00
Ambrx Biopharma Inc. ( AMAM ) Owners' Earnings Annual ($MM) is 0.00
Ambrx Biopharma Inc. ( AMAM ) Current Price to Owners' Earnings ratio is 0.00
Ambrx Biopharma Inc. ( AMAM ) EBITDA TTM ($MM) is -58.80
Ambrx Biopharma Inc. ( AMAM ) EBITDA Margin is -1997.27%
Capital Allocation:
Ambrx Biopharma Inc. ( AMAM ) has paid 0.00 dividends per share and bought back -23.630194 million shares in the past 12 months
Ambrx Biopharma Inc. ( AMAM ) has reduced its debt by 1.624 million USD in the last 12 months
Capital Structure:
Ambrx Biopharma Inc. ( AMAM ) Interest-bearing Debt ($MM) as of last quarter is 11
Ambrx Biopharma Inc. ( AMAM ) Annual Working Capital Investments ($MM) are -68
Ambrx Biopharma Inc. ( AMAM ) Book Value ($MM) as of last quarter is 242
Ambrx Biopharma Inc. ( AMAM ) Debt/Capital as of last quarter is 6%
Other Balance Sheet Stats:
Ambrx Biopharma Inc. ( AMAM ) has 225 million in cash on hand as of last quarter
Ambrx Biopharma Inc. ( AMAM ) has 18 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Ambrx Biopharma Inc. ( AMAM ) has 62 common shares outstanding as of last quarter
Ambrx Biopharma Inc. ( AMAM ) has 0 million USD of preferred stock value
Academic Scores:
Ambrx Biopharma Inc. ( AMAM ) Altman Z-Score is 17.53 as of last quarter
Ambrx Biopharma Inc. ( AMAM ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Ambrx Biopharma Inc. ( AMAM ) largest shareholder is Holocene Advisors, LP owning 913754 shares at 12.78 ($MM) value
Cormorant Asset Management, Lp(an insider) Bought 500000 shares of Ambrx Biopharma Inc. ( AMAM ) for the amount of $5075000.00 on 2023-03-16
25.38% of Ambrx Biopharma Inc. ( AMAM ) is held by insiders, and 78.67% is held by institutions
Ambrx Biopharma Inc. ( AMAM ) went public on 2021-06-18
Other Ambrx Biopharma Inc. ( AMAM ) financial metrics:
FCF:-60.82
Unlevered Free Cash Flow:0.00
EPS:-1.48
Operating Margin:-48350.94
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-37.94
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Ambrx Biopharma Inc. ( AMAM ) :
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. The company's lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. It is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, the company is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.